Welcome to our dedicated page for Eloxx Pharmaceuticals news (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eloxx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eloxx Pharmaceuticals's position in the market.
Eloxx Pharmaceuticals announced the pricing of a public offering of 33,333,334 shares at $1.35 per share. The underwriters have a 30-day option to purchase an additional 5,000,000 shares. The offering, managed by B. Riley Securities, is expected to close around May 18, 2021, pending standard conditions. This common stock sale is authorized under a previously effective shelf registration statement with the SEC, ensuring compliance with regulatory requirements. The company emphasizes that this announcement does not constitute an offer to sell securities.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) has initiated an underwritten public offering of its common stock. The offering includes a potential 30-day option for underwriters to purchase an additional 15% of the shares. B. Riley Securities, Inc. is the sole book-running manager for this offering, which is contingent on market conditions. The shares will be offered under a previously effective SEC registration statement. Full details will be provided in a final prospectus supplement.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced its acquisition of Zikani Therapeutics and reported its Q1 2021 financial results. The acquisition aims to enhance the potential of ELX-02, a treatment for cystic fibrosis, now in Phase 2 trials, which has added a new arm evaluating its safety with Kalydeco. The CF Foundation has increased funding for clinical trials in Europe and Israel. Eloxx reported a Q1 net loss of $8.7 million but improved from a $13.9 million loss the previous year. Cash reserves stood at $18.2 million, expected to sustain operations through Q3 2021.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced a fifth treatment arm in its ongoing Phase 2 clinical trial for ELX-02, aimed at treating cystic fibrosis (CF) in patients with at least one G542X allele. This addition evaluates the safety of ELX-02 in combination with Kalydeco (ivacaftor). Positive preclinical synergy between the two drugs suggests enhanced clinical outcomes. Results from the first four arms are anticipated in the second half of 2021. The trial spans multiple countries, with no serious drug-related adverse events reported thus far.
Eloxx Pharmaceuticals (NASDAQ: ELOX) has acquired Zikani Therapeutics in an all-stock transaction, aiming to lead in ribosomal RNA-targeted therapies for rare diseases and oncology. The merger enhances the potential of ELX-02, currently in Phase 2 for cystic fibrosis, and introduces new therapeutic opportunities for Recessive Dystrophic Epidermolysis Bullosa and related conditions. Zikani's TURBO-ZM™ platform will accelerate drug development. Approximately 7.6 million shares will be issued to Zikani stockholders, granting them 16% ownership of the combined entity.
Eloxx Pharmaceuticals (NASDAQ: ELOX) reported financial results for Q4 and FY 2020, noting cash reserves of $24.7 million to support operations. The company is set to release top-line data from its Phase 2 cystic fibrosis trials in H1 2021, expanding sites internationally, including Australia and Canada. The Cystic Fibrosis Foundation increased funding, and dose escalation has been approved by independent committees without serious adverse events. Eloxx aims to demonstrate the efficacy of ELX-02, its investigational drug, in treating cystic fibrosis.
Summary:
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced a conference call and webcast scheduled for March 11, 2021, at 4:30 p.m. ET to discuss its Q4 and full-year 2020 financial and operational results. The company focuses on developing RNA-modulating therapies for diseases caused by nonsense mutations, with its lead candidate, ELX-02, targeting cystic fibrosis. Eloxx aims to restore functional protein production in affected patients. This press release includes forward-looking statements regarding the company's development plans and potential risks associated with its drug candidates.
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) announced the publication of a scientific manuscript in the Journal of Cystic Fibrosis, detailing the results of ELX-02 in restoring CFTR function in human-derived intestinal organoids. The findings indicate that ELX-02 increased CFTR activity in a dose-dependent manner, showing a 5-fold increase in CFTR mRNA compared to vehicle treatment. The study supports the ongoing Phase 2 clinical trial for patients with G542X nonsense alleles, who currently have limited treatment options. Top-line data is expected in the first half of 2021.
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) announced the publication of a scientific manuscript detailing the results of a Phase 1B trial for its drug candidate ELX-02, aimed at treating cystic fibrosis. Published in the Journal of Clinical Pharmacology in Drug Development, the study found no serious adverse events, supporting the drug's favorable safety profile. Dr. Goddeeris expressed optimism regarding ongoing Phase 2 trials and anticipates top-line data in the first half of 2021. Eloxx focuses on RNA-modulating therapies for diseases caused by nonsense mutations.
Eloxx Pharmaceuticals announced the publication of a scientific manuscript detailing the results of its Phase 1 renal impairment trial for ELX-02 in patients with nephropathic cystinosis. The study found that ELX-02 was well tolerated and demonstrated a consistent pharmacokinetic profile across varying degrees of renal insufficiency. This research enables targeted individualized dosing of ELX-02, supporting ongoing Phase 2 programs in both cystic fibrosis and autosomal dominant polycystic kidney disease. The findings were published in the Journal of Clinical Pharmacology.